0001415889-22-012355.txt : 20221209 0001415889-22-012355.hdr.sgml : 20221209 20221209180025 ACCESSION NUMBER: 0001415889-22-012355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221207 FILED AS OF DATE: 20221209 DATE AS OF CHANGE: 20221209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eldridge George A CENTRAL INDEX KEY: 0001413006 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 221455807 MAIL ADDRESS: STREET 1: C/O TARGANTA THERAPEUTICS CORPORATION STREET 2: 222 THIRD STREET SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-12092022_061201.xml X0306 4 2022-12-07 0001798749 Aerovate Therapeutics, Inc. AVTE 0001413006 Eldridge George A C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SEE REMARKS Common Stock 2022-12-07 4 M 0 11637 2.14 A 13597 D Common Stock 2022-12-07 4 S 0 7079 19.3657 D 6518 D Common Stock 2022-12-07 4 S 0 4558 20.4021 D 1960 D Common Stock 2022-12-08 4 M 0 12011 2.14 A 13971 D Common Stock 2022-12-08 4 S 0 960 20.1185 D 13011 D Common Stock 2022-12-08 4 S 0 20 20.58 D 12991 D Common Stock 2022-12-08 4 S 0 11031 24.2022 D 1960 D Stock Option (Right to Buy) 2.14 2022-12-07 4 M 0 11637 0 D 2031-04-01 Common Stock 11637 84656 D Stock Option (Right to Buy) 2.14 2022-12-08 4 M 0 1887 0 D 2031-04-01 Common Stock 1887 82769 D Stock Option (Right to Buy) 2.14 2022-12-08 4 M 0 10124 0 D 2031-04-01 Common Stock 10124 40726 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.575 to $20.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Officer Title: Chief Financial Officer and Treasurer /s/ George A. Eldridge 2022-12-09